OTC Markets Group Welcomes Medicenna Therapeutics to OTCQX

NEW YORK, Oct. 18, 2017 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Medicenna Therapeutics Corp. (TSX: MDNA; OTCQX: MDNAF), a clinical stage immuno-oncology company, has qualified to trade on the OTCQX® Best Market.

Medicenna Therapeutics begins trading today on OTCQX under the symbol "MDNAF."  U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

"Medicenna Therapeutics joins an impressive roster of Canadian companies, including more than 25 added this year, that cross-trade their shares on the OTCQX market to maximize their reach to U.S. investors. Trading on OTCQX will enable Medicenna to efficiently broaden accessibility to their news and financial disclosure and build visibility among U.S. investors," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group.

"Trading on the OTCQX will improve the Company's ability to attract a wider audience of investors from both inside and outside the United States. This corporate milestone will provide additional visibility within the investment community enabling us to build awareness more broadly and expand our current shareholder base in order to drive shareholder value," said Elizabeth Williams, Chief Financial Officer of Medicenna.

Medicenna Therapeutics was sponsored for OTCQX by Burns Figa & Will PC, a qualified third-party firm responsible for providing guidance on OTCQX requirements and recommending membership. 

About Medicenna Therapeutics
Medicenna is a clinical stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkinestm and first in class Empowered Cytokinestm (ECs).  Its wholly owned subsidiary, Houston-based Medicenna BioPharma, is specifically targeting the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Medicenna's lead IL4-EC, MDNA55 is enrolling patients in a CPRIT (Cancer Prevention and Research Institute of Texas) funded Phase 2b clinical trial for recurrent glioblastoma (rGBM) at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment, offering a unique treatment paradigm for a large majority of cancer patients.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 U.S. and global securities.  Through OTC Link® ATS, we connect a diverse network of broker-dealers that provide liquidity and execution services.  We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.
To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, [email protected]

SOURCE OTC Markets Group Inc.